Literature DB >> 27256309

DNA Methylation Signature Reveals Cell Ontogeny of Renal Cell Carcinomas.

Gabriel G Malouf1,2, Xiaoping Su3, Jianping Zhang3, Chad J Creighton4, Thai H Ho5,6, Yue Lu7, Noël J-M Raynal8, Jose A Karam9, Pheroze Tamboli10, Frederick Allanick2, Roger Mouawad2, Jean-Philippe Spano11,2, David Khayat11,2, Christopher G Wood9, Jaroslav Jelinek7, Nizar M Tannir12.   

Abstract

PURPOSE: DNA methylation is a heritable covalent modification that is developmentally regulated and is critical in tissue-type definition. Although genotype-phenotype correlations have been described for different subtypes of renal cell carcinoma (RCC), it is unknown if DNA methylation profiles correlate with morphological or ontology based phenotypes. Here, we test the hypothesis that DNA methylation signatures can discriminate between putative precursor cells in the nephron. EXPERIMENTAL DESIGNS: We performed deep profiling of DNA methylation and transcriptome in diverse histopathological RCC subtypes and validated DNA methylation in an independent dataset as well as in The Cancer Genome Atlas Clear Cell and Chromophobe Renal Cell Carcinoma Datasets.
RESULTS: Our data provide the first mapping of methylome epi-signature and indicate that RCC subtypes can be grouped into two major epi-clusters: C1, which encompasses clear-cell RCC, papillary RCC, mucinous and spindle cell carcinomas and translocation RCC; C2, which comprises oncocytoma and chromophobe RCC. Interestingly, C1 epi-cluster displayed 3-fold more hypermethylation as compared with C2 epi-cluster. Of note, differentially methylated regions between C1 and C2 epi-clusters occur in gene bodies and intergenic regions, instead of gene promoters. Transcriptome analysis of C1 epi-cluster suggests a functional convergence on Polycomb targets, whereas C2 epi-cluster displays DNA methylation defects. Furthermore, we find that our epigenetic ontogeny signature is associated with worse outcomes of patients with clear-cell RCC.
CONCLUSIONS: Our data define the epi-clusters that can discriminate between distinct RCC subtypes and for the first time define the epigenetic basis for proximal versus distal tubule derived kidney tumors. Clin Cancer Res; 22(24); 6236-46. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2016        PMID: 27256309      PMCID: PMC5135666          DOI: 10.1158/1078-0432.CCR-15-1217

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  35 in total

1.  The somatic genomic landscape of chromophobe renal cell carcinoma.

Authors:  Caleb F Davis; Christopher J Ricketts; Min Wang; Lixing Yang; Andrew D Cherniack; Hui Shen; Christian Buhay; Hyojin Kang; Sang Cheol Kim; Catherine C Fahey; Kathryn E Hacker; Gyan Bhanot; Dmitry A Gordenin; Andy Chu; Preethi H Gunaratne; Michael Biehl; Sahil Seth; Benny A Kaipparettu; Christopher A Bristow; Lawrence A Donehower; Eric M Wallen; Angela B Smith; Satish K Tickoo; Pheroze Tamboli; Victor Reuter; Laura S Schmidt; James J Hsieh; Toni K Choueiri; A Ari Hakimi; Lynda Chin; Matthew Meyerson; Raju Kucherlapati; Woong-Yang Park; A Gordon Robertson; Peter W Laird; Elizabeth P Henske; David J Kwiatkowski; Peter J Park; Margaret Morgan; Brian Shuch; Donna Muzny; David A Wheeler; W Marston Linehan; Richard A Gibbs; W Kimryn Rathmell; Chad J Creighton
Journal:  Cancer Cell       Date:  2014-08-21       Impact factor: 31.743

2.  Chromatin organization is a major influence on regional mutation rates in human cancer cells.

Authors:  Benjamin Schuster-Böckler; Ben Lehner
Journal:  Nature       Date:  2012-08-23       Impact factor: 49.962

3.  Chromophobe renal cell carcinoma: a clinicopathologic study of 203 tumors in 200 patients with primary resection at a single institution.

Authors:  Christopher G Przybycin; Angel M Cronin; Farbod Darvishian; Anuradha Gopalan; Hikmat A Al-Ahmadie; Samson W Fine; Ying-bei Chen; Melanie Bernstein; Paul Russo; Victor E Reuter; Satish K Tickoo
Journal:  Am J Surg Pathol       Date:  2011-07       Impact factor: 6.394

4.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

Review 5.  The Heidelberg classification of renal cell tumours.

Authors:  G Kovacs; M Akhtar; B J Beckwith; P Bugert; C S Cooper; B Delahunt; J N Eble; S Fleming; B Ljungberg; L J Medeiros; H Moch; V E Reuter; E Ritz; G Roos; D Schmidt; J R Srigley; S Störkel; E van den Berg; B Zbar
Journal:  J Pathol       Date:  1997-10       Impact factor: 7.996

6.  DNA methylation profiling distinguishes histological subtypes of renal cell carcinoma.

Authors:  Amy A Slater; Majed Alokail; Dean Gentle; Masahiro Yao; Gyula Kovacs; Eamonn R Maher; Farida Latif
Journal:  Epigenetics       Date:  2013-02-21       Impact factor: 4.528

7.  Conserved DNA methylation patterns in healthy blood cells and extensive changes in leukemia measured by a new quantitative technique.

Authors:  Jaroslav Jelinek; Shoudan Liang; Yue Lu; Rong He; Louis S Ramagli; Elizabeth J Shpall; Marcos R H Estecio; Jean-Pierre J Issa
Journal:  Epigenetics       Date:  2012-10-17       Impact factor: 4.528

8.  Genomic heterogeneity of translocation renal cell carcinoma.

Authors:  Gabriel G Malouf; Federico A Monzon; Jérôme Couturier; Vincent Molinié; Bernard Escudier; Philippe Camparo; Xiaoping Su; Hui Yao; Pheroze Tamboli; Dolores Lopez-Terrada; Maria Picken; Marileila Garcia; Asha S Multani; Sen Pathak; Christopher G Wood; Nizar M Tannir
Journal:  Clin Cancer Res       Date:  2013-07-01       Impact factor: 12.531

Review 9.  The C/EBP family of transcription factors: a paradigm for interaction between gene expression and proliferation control.

Authors:  Claus Nerlov
Journal:  Trends Cell Biol       Date:  2007-07-19       Impact factor: 20.808

Review 10.  DNA methylation profiling in the clinic: applications and challenges.

Authors:  Holger Heyn; Manel Esteller
Journal:  Nat Rev Genet       Date:  2012-09-04       Impact factor: 53.242

View more
  23 in total

Review 1.  The epigenetic landscape of renal cancer.

Authors:  Mark R Morris; Farida Latif
Journal:  Nat Rev Nephrol       Date:  2016-11-28       Impact factor: 28.314

2.  Incorporating DNA Methyltransferase Inhibitors (DNMTis) in the Treatment of Genitourinary Malignancies: A Systematic Review.

Authors:  Michal Chovanec; Fadi Taza; Maitri Kalra; Noah Hahn; Kenneth P Nephew; Michael J Spinella; Costantine Albany
Journal:  Target Oncol       Date:  2018-02       Impact factor: 4.493

Review 3.  Renal Medullary Carcinoma: Establishing Standards in Practice.

Authors:  Kathryn E Beckermann; Deva Sharma; Shruti Chaturvedi; Pavlos Msaouel; Miguel R Abboud; Yves Allory; Franck Bourdeaut; Julien Calderaro; Aguirre A de Cubas; Vimal K Derebail; Andrew L Hong; Rakhi P Naik; Gabriel G Malouf; Elizabeth A Mullen; Victor E Reuter; Charles W M Roberts; Cheryl L Walker; Christopher G Wood; Michael R DeBaun; Hendrik Van Poppel; Nizar M Tannir; W Kimryn Rathmell
Journal:  J Oncol Pract       Date:  2017-07       Impact factor: 3.840

4.  A Pan-Cancer Analysis Revealing the Dual Roles of Lysine (K)-Specific Demethylase 6B in Tumorigenesis and Immunity.

Authors:  Jia-Tong Ding; Xiao-Ting Yu; Jin-Hao He; De-Zhi Chen; Fei Guo
Journal:  Front Genet       Date:  2022-06-14       Impact factor: 4.772

Review 5.  The Role of DNA Methylation in Renal Cell Carcinoma.

Authors:  Brittany N Lasseigne; James D Brooks
Journal:  Mol Diagn Ther       Date:  2018-08       Impact factor: 4.074

Review 6.  The Role of Epigenetics in the Progression of Clear Cell Renal Cell Carcinoma and the Basis for Future Epigenetic Treatments.

Authors:  Javier C Angulo; Claudia Manini; Jose I López; Angel Pueyo; Begoña Colás; Santiago Ropero
Journal:  Cancers (Basel)       Date:  2021-04-25       Impact factor: 6.639

7.  Methylomes of renal cell lines and tumors or metastases differ significantly with impact on pharmacogenes.

Authors:  Stefan Winter; Pascale Fisel; Florian Büttner; Steffen Rausch; Debora D'Amico; Jörg Hennenlotter; Stephan Kruck; Anne T Nies; Arnulf Stenzl; Kerstin Junker; Marcus Scharpf; Ute Hofmann; Heiko van der Kuip; Falko Fend; German Ott; Abbas Agaimy; Arndt Hartmann; Jens Bedke; Matthias Schwab; Elke Schaeffeler
Journal:  Sci Rep       Date:  2016-07-20       Impact factor: 4.379

Review 8.  Targeting DNA Methyltranferases in Urological Tumors.

Authors:  Ângela Marques-Magalhães; Inês Graça; Rui Henrique; Carmen Jerónimo
Journal:  Front Pharmacol       Date:  2018-04-13       Impact factor: 5.810

9.  Improving needle biopsy accuracy in small renal mass using tumor-specific DNA methylation markers.

Authors:  Sameer Chopra; Jie Liu; Mehrdad Alemozaffar; Peter W Nichols; Manju Aron; Daniel J Weisenberger; Clayton K Collings; Sumeet Syan; Brian Hu; Mihir Desai; Monish Aron; Vinay Duddalwar; Inderbir Gill; Gangning Liang; Kimberly D Siegmund
Journal:  Oncotarget       Date:  2017-01-17

10.  ACE2 correlated with immune infiltration serves as a prognostic biomarker in endometrial carcinoma and renal papillary cell carcinoma: implication for COVID-19.

Authors:  Jing Yang; Hongxia Li; Shengda Hu; Yafeng Zhou
Journal:  Aging (Albany NY)       Date:  2020-04-27       Impact factor: 5.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.